Analyst Nevin Varghese maintained a "buy" rating on Pharvaris on November 12, setting a target price of $63.00. The company's stock closed at $33.83 yesterday.
According to the data from TipRanks, Varghese is a 2-star analyst with an average return rate of 7.0% and a success rate of 62.50%. Varghese covers the healthcare sector, with a focus on tracking stocks such as Pharvaris, Climb Bio, and Prothena.
Pharvaris is currently rated as a "strong buy" by all analysts, with a consensus target price of $61.42, which indicates an upside potential of 81.55% compared to the current stock price. In a report released yesterday, Oppenheimer also maintained a "buy" rating for the stock and set a target price of $75.00.
According to the latest financial report for the quarter ending June 30th as per Pharvaris, the company reported a quarterly net loss of $47.84 million for GAAP. In contrast, during the same period last year, the net loss was $45.48 million for GAAP.
Based on the trading activities of 72 company insiders recently, the sentiment among these insiders is relatively negative regarding this stock. This indicates that, in the past quarter, there has been an increase in the number of insiders selling PHVS shares compared to earlier this year. The most recent instance occurred in September 2026, when PHVS director Monges Viviane sold 11,969 shares for a total transaction amount of $395,455.76.
